Patents by Inventor Phillip KRAPF

Phillip KRAPF has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for the production of 18F-labeled active esters and their application exemplified by the preparation of a PSMA-specific PET-tracer
    Patent number: 10112974
    Abstract: Novel efficient, time-saving and reliable radiofluorination procedures for the production of 18F-labelled active esters via nucleophilic substitution of the corresponding onium precursors with 18F? are described. The active ester including [18F]F-Py-TFP and [18F]TFB produced by one of these methods was used to prepare PSMA-specific PET tracers such as [18F]DCFPyL. The key advantages of these inventive methods are efficiency, short time of preparation and excellent amenability to automation. A pharmaceutical composition containing at least one PSMA-specific PET tracers prepared by the inventive method is useful for positron emission tomography (PET) imaging, especially imaging prostate tumor.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: October 30, 2018
    Assignees: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V., Universitat Zu Koln
    Inventors: Bernd Neumaier, Boris Zlatopolskiy, Raphael Richarz, Phillip Krapf
  • Novel method for the production of 18F-labeled active esters and their application exemplified by the preparation of a PSMA-specific PET-tracer
    Publication number: 20170267717
    Abstract: Novel efficient, time-saving and reliable radiofluorination procedures for the production of 18F-labelled active esters via nucleophilic substitution of the corresponding onium precursors with 18F? are described. The active ester including [18F]F-Py-TFP and [18F]TFB produced by one of these methods was used to prepare PSMA-specific PET tracers such as [18F]DCFPyL. The key advantages of these inventive methods are efficiency, short time of preparation and excellent amenability to automation. A pharmaceutical composition containing at least one PSMA-specific PET tracers prepared by the inventive method is useful for positron emission tomography (PET) imaging, especially imaging prostate tumor.
    Type: Application
    Filed: August 24, 2015
    Publication date: September 21, 2017
    Applicant: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Bernd NEUMAIER, Boris ZLATOPOLSKIY, Raphael RICHARZ, Phillip KRAPF